Abstract
Pancreatic cancer has long carried poor prognosis. The development of new therapeutic approaches is particularly urgent. Inactivation of the tumor-suppressor gene p16 INK4a/CDKN2, a specific inhibitor of the cyclin-dependent kinases CDK4 and CDK6, is the most common genetic alteration in human pancreatic cancer, making it an ideal target for gene replacement. Here we transfected tumor cells using a recombinant adenovirus containing the wt- p16 cDNA (Ad5RSV- p16 ). The overexpression of p16 decreased cell proliferation in all four human pancreatic tumor cell lines (NP-9, NP-18, NP-29, and NP-31). However, G1 arrest and senescence were observed in only three. In contrast, the fourth (NP-18) showed a significant increase in apoptosis. This differential behavior may be related to the differences found in the expression level of E2F-1. Experiments on subcutaneous pancreatic xenografts demonstrated the effectiveness of p16 in the inhibition of pancreatic tumor growth in vivo. Taken together, our results indicate that approaches involving p16 replacement are promising in pancreatic cancer treatment. Cancer Gene Therapy (2001) 8, 740–750
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo PA . Cancer statistics, 1998 CA Cancer J Clin 1998 48: 6–29
Evans DB, Abbruzzese JL, Rich TA . Cancer of the pancreas In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed Philadelphia: Lippincott-Raven 1997 1054–1081
Guzburg WH, Salmons B . Novel clinical strategies for the treatment of pancreatic carcinoma Trends Mol Med 2001 7: 30–37
Roth JA, Cristiano RJ . Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997 89: 21–39
Gómez-Navarro J, Curiel DT, Douglas JT . Gene therapy for cancer Eur J Cancer 1999 35: (14) 2039–2057
Vile RG, Russell SJ, Lemoine NR . Cancer gene therapy: hard lessons and new courses Gene Ther 2000 7: 2–8
King KL, Cidlowski JA . Cell cycle and apoptosis: common pathways to life and death J Cell Biochem 1995 8: 175–185
Culver KW, Blaese RM . Gene therapy for cancer Trends Genet 1994 10: 174–178
Favrot M, Coll JL, Louis N, Negoescu A . Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy Gene Ther 1998 5: 728–739
Sherr CJ . The Pezcoller lecture: cancer cell cycles revisited Cancer Res 2000 60: 3689–3695
Chin L, Pomerantz J, DePinho RA . The INK4a/ARF tumor suppressor: one gene–two products–two pathways Trends Biochem Sci 1998 23: 291–296
Yap DBS, Hsieb JK, Chan FSG, Lu X . Mdm-2: a bridge over the two tumour suppressors, p53 and pRb Oncogene 1999 18: 7681–7689
Weinberg RA . The retinoblastoma protein and cell cycle control Cell 1995 81: 323–330
Lundberg AS, Weinberg RA . Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin–cdk complexes Mol Cell Biol 1998 18: (2) 753–761
Graña X, Reddy EP . Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) Oncogene 1995 11: 211–219
Sherr CJ, Roberts M . CDK inhibitors: positive and negative regulators of G1-phase progression Genes & Dev 1999 13: 1501–1512
Graña X, Garriga J, Mayol X . Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth Oncogene 1998 17: 3365–3383
Müller H, Bracken AP, Vernell R, et al . E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis Genes Dev 2001 15: 267–285
Saphiro GI, Rollins BJ . p16INK4A as a human tumor suppressor Biochim Biophys Acta 1996 1242: 165–169
Caldas C, Hahn SA, da Costa LT, et al . Frequent somatic mutations and homozygous deletions of the MTS1 gene in pancreatic adenocarcinoma Nat Genet 1994 8: 27–32
Serrano M, Hannon GJ, Beach D . A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4 Nature 1993 366: 704–707
Lukas J, Parry D, Aagaard L, et al . Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16 Nature 1995 375: 503–506
Alcorta DA, Xiong Y, Phelps D, et al . Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts Proc Natl Acad Sci USA 1996 93: 13742–13747
Robles SJ, Adami GR . Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts Oncogene 1998 16: 1113–1123
Serrano M, Gómez-Lahoz RA, DePinho RA, et al . Inhibition of ras-induced proliferation and cellular transformation by p16INK4A Science 1996 267: 249–252
Serrano M, Lin AW, McCurrach ME, et al . Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16Ink4a Cell 1997 88: 593–602
Rocco JW, Li D, Liggett WH, et al . p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer Clin Cancer Res 1998 4: 1697–1704
Craig C, Kim M, Ohri E, et al . Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells Oncogene 1998 16: 265–272
Uhrbom D, Nister M, Westermark B . Induction of senescence in human malignant glioma cells by p16INK4A Oncogene 1997 15: 505–514
Steiner MS, Zhang Y, Farooq F, et al . Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence Cancer Gene Ther 2000 7: (3) 360–372
Fueyo J, Gómez-Manzano C, Yung WKA, et al . Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells Oncogene 1996 12: 103–110
Harada H, Nakagawa K, Iwata S, et al . Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas Cancer Res 1999 59: 3783–3789
Chintala SK, Fueyo J, Gómez-Manzano C, et al . Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro Oncogene 1997 15: 2049–2057
Wieser RJ, Faust D, Dietrich C, Oesch F . p16INK4 mediates contact inhibition of growth Oncogene 1999 18: 277–281
Fahraeus R, Lane DP . The p16INK4a tumour suppressor protein inhibits alpha-v-beta-3 integrin–mediated cell spreading on vitronectin by blocking PKC-dependent localization of alpha-v-beta-3 to focal contacts EMBO J 1999 18: 2106–2118
Schreiber M, Muller WJ, Singh G, Graham FL . Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21WAF1/CIP1, and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity Oncogene 1999 18: 1663–1676
Frizelle SP, Grim J, Zhou J, et al . Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression Oncogene 1998 16: 3087–3095
Naruse I, Heikese I, Heike Y, Hama S, Mori M, Saijo N . High concentrations of recombinant adenovirus expressing p16 gene induces apoptosis in lung cancer lines Anticancer Res 1998 18: 4275–4282
Ghaaneh P, Grenhalf W, Humphreys M, et al . Adenovirus-mediated transfer of p53 and p16INK4a results in pancreatic cancer regression in vitro and in vivo Gene Ther 2001 8: 199–208
Villanueva A, García C, Paules AB, et al . Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cells Oncogene 1998 17: 1969–1978
Cascalló M, Mercadé E, Lluís F, et al . Genetic background determines the response to adenovirus-mediated wt- p53 expression in human pancreatic tumor cells Cancer Gene Ther 1999 6: 428–436
Darzynkiewicz Z, Li X, Gong J, Hara S, Traganos F . Analysis of cell death by flow cytometry In: Studzinski GP, ed. Cell Growth and Apoptosis: A Practical Approach, 1st ed NY: Oxford Univ. Press 1995 143–167
Dimri GP, Lee X, Basile G, et al . A biomarker that identifies senescent human cells in culture and aging skin in vivo Proc Natl Acad Sci USA 1995 92: 9363–9367
Cascalló M, Calbó J, Gelpí JLl, Mazo A . Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer Cancer Gene Ther 2000 7: 545–556
Becker TC, Noel RJ, Coats WS, et al . Use of recombinant adenovirus for metabolic engineering of mammalian cells Methods Cell Biol 1994 5: 161–189
Bramson JL, Hitt M, Gauldie J, Graham FL . Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector Gene Ther 1997 4: 1069–1076
Humphreys M, Greenhalf W, Neoptolemos JP, Ghaneh P . The potential for gene therapy in pancreatic cancer Int J Pancreatol 1999 26: 5–21
Peng KW . Strategies for targeting therapeutic gene delivery Mol Med Today 1999 5: 448–453
Arap W, Nishikawa R, Furnari FB, Cavenee WK, et al . Replacement of the p16/CDKN2 gene suppresses human glioma cell growth Cancer Res 1995 55: 1351–1354
Bartek J, Bartkova J, Lukas J . The retinoblastoma protein pathway in cell cycle control and cancer Exp Cell Res 1997 237: 1–6
Sandig K, Brandt K, Herwig S, et al . Adenovirally transferred p16 and p53 genes cooperate to induce apoptotic tumor cell death Nat Med 1997 3: 313–319
Kataoka M, Wiehle S, Spitz F, et al . Down-regulation of bcl-2 is associated with p16INK4-mediated apoptosis in non-small cell lung cancer cells Oncogene 2000 19: 1589–1595
Fang X, Jin X, Xu HJ, et al . Expression of p16 induces transcriptional downregulation of the RB gene Oncogene 1998 16: 1–8
Holmberg C, Helin K, Sehested M, Karlström O . E2F-1–induced p53-independent apoptosis in transgenic mice Oncogene 1998 17: 143–155
Steiner M, Wang Y, Zhang Y, et al . p16/MTS1/INK4A suppresses prostate cancer by both pRb-dependent and -independent pathways Oncogene 2000 19: 1297–1306
Plath T, Detjen K, Welzel M, et al . A novel function for the tumor suppressor p16INK4a: induction of anoikis via upregulation of the α5β1 fibronectin receptor J Cell Biol 2000 150: 1467–1477
Rizk NP, Chang MY, El-Kouri C, et al . The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer Cancer Gene Ther 1999 6: (4) 1–301
Acknowledgements
This research was supported by Comisión Interministerial de Ciencia y Tecnología, Grant SAF98/042. J. C. is a recipient of predoctoral fellowship from Ministerio de Educación y Cultura. We acknowledge the help received from Jaume Comas, who is in charge of flow cytometry section in the Serveis Científico-Tècnics de la Universitat de Barcelona. We thank Agnès Figueras and Meritxell Carrió for their technical assistance, Ignasi Catalán for the statistical analysis and Robin Rycroft for his editorial help.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calbó, J., Marotta, M., Cascalló, M. et al. Adenovirus-mediated wt- p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 8, 740–750 (2001). https://doi.org/10.1038/sj.cgt.7700374
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700374
Keywords
This article is cited by
-
p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors
Oncogene (2011)
-
The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity
Cell Death & Differentiation (2004)
-
Anti-migratory and anti-angiogenic effect of p16: A novel localization at membrane ruffles and lamellipodia in endothelial cells
Angiogenesis (2004)